Fluralaner 13.64% 12-Week Chew

Verify with FDA CVM →

26,358 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
26,358
Total Reports
667
Deaths Reported
250.0%
Death Rate

Active Ingredients

Fluralaner 13.64% 12-Week Chew

Administration Routes

OralUnknownTopicalOtherDentalImmersionOropharyngealRectal

Species Affected

Dog 24,519
Unknown 1,758
Cat 40
Human 32
Goat 3
Fox 2
Horse 1
Other 1
Chicken 1
Other Canids 1

Most Affected Breeds

Crossbred Canine/dog 6,200
Unknown 1,834
Retriever - Labrador 1,782
Dog (unknown) 1,372
Retriever - Golden 955
Chihuahua 910
Shepherd Dog - German 883
Shih Tzu 727
Terrier - Yorkshire 720
Shepherd Dog - Australian 636

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 7,207
Vomiting 6,194
Lack of efficacy (ectoparasite) - tick NOS 2,804
Emesis (multiple) 1,982
Seizure NOS 1,287
Diarrhoea 1,254
UNPALATABLE 1,207
Lethargy (see also Central nervous system depression in 'Neurological') 1,121
Product Defect, General 1,049
Lack of efficacy (bacteria) - Borrelia 892
Lack of efficacy (bacteria) - NOS 857
Drug administration error 720

Outcome Breakdown

Ongoing
14,359 (58.3%)
Recovered/Normal
8,261 (33.6%)
Outcome Unknown
1,096 (4.5%)
Euthanized
339 (1.4%)
Died
328 (1.3%)
Recovered with Sequela
235 (1.0%)

Data Summary

Metric Value
Total adverse event reports 26,358
Reports involving death 667
Case-fatality rate (reported events) 250.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Fluralaner 13.64% 12-Week Chew Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 26,358 adverse event reports referencing Fluralaner 13.64% 12-Week Chew, including 667 reports in which the animal died — a 250.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Fluralaner 13.64% 12-Week Chew. Reported administration routes include Oral, Unknown, Topical, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Fluralaner 13.64% 12-Week Chew reports are Dog (24,519 reports), Unknown (1,758 reports), Cat (40 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (6,200), Unknown (1,834), Retriever - Labrador (1,782) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Fluralaner 13.64% 12-Week Chew are Lack of efficacy (ectoparasite) - flea (7,207), Vomiting (6,194), Lack of efficacy (ectoparasite) - tick NOS (2,804), Emesis (multiple) (1,982). Of the 24,618 reports with a coded outcome, Ongoing is the leading category at 58.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Fluralaner 13.64% 12-Week Chew.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial